CClinicalTrials.gg
Sign In
Not yet recruitingNCT07337174Updated Jan 13, 2026

Study to Compare and Evaluate the Safety and Pharmacokinetics After Subcutaneous Injection of HUC2-676 or HUC2-676-R in Healthy Adult Subjects

A Phase 1 interventional study of HUC2-676 and HUC2-676-R in Obesity, sponsored by Huons Co., Ltd.. Not yet recruiting. Open to participants aged 19 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-13.

Sponsored by Huons Co., Ltd. · Phase 1, Interventional, and Treatment

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
19 Years to 65 Years
Sex
All
01

Study summary

The trial uses a randomized, open-label, single-dose administration per period, and a 2 x 2 crossover design where subjects receive both treatments sequentially with a washout.

02

Conditions studied

  • Obesity

Browse trials for

03

Who can participate

Ages eligible
19 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Healthy adult volunteers aged 19 to 65 years, inclusive, at screening.
  • Subjects who have been fully informed of the details of this clinical trial, have fully understood the information, have voluntarily decided to participate, and have provided written informed consent to comply with all protocol requirements throughout the trial period.

Exclusion criteria

Exclusion Criteria:

  • Subjects with a current or past clinically significant medical history of hepatic, renal, neurological, psychiatric, respiratory, endocrine, hematologic, oncologic, genitourinary, cardiovascular, gastrointestinal, musculoskeletal, or other disorders.
  • For females: Pregnant women (positive urine hCG) or nursing mothers.
04

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    HUC2-676

    Drug: HUC2-676

  • Active comparator
    HUC2-676-R

    Drug: HUC2-676-R

Interventions

  • DrugHUC2-676

    subcutaneous injection

  • DrugHUC2-676-R

    subcutaneous injection

05

What researchers measure

Primary outcomes

  1. Cmax following single-dose administration

    Time frame: 0 through 72 hours post-dose

  2. AUC following single-dose administration

    Time frame: 0 through 72 hours post-dose

06

Study locations

No study locations are listed for this record.

07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07337174
Lead sponsor
Huons Co., Ltd.
Responsible party
Sponsor
First posted
Jan 13, 2026
Start date
Jan 25, 2026 (estimated)
Primary completion
Mar 24, 2026 (estimated)
Completion
Mar 24, 2026 (estimated)
Last update
Jan 13, 2026

Study contacts

Huons
Contact
rlee@huons.com
82-070-7492-6091
Park
principal investigator · Chungbuk National University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Obesity→

Other studies from this sponsor

Huons Co., Ltd.

Start the discussion